 | • レポートコード：MMG23DC12388 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英語、PDF、60ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User（1名様閲覧用） | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Multi User（20名様閲覧用） | ￥633,750 (USD4,225) | ▷ お問い合わせ |
| Enterprise User（閲覧人数制限なし） | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の長鎖ペプチド医薬品市場規模と予測を収録しています。・世界の長鎖ペプチド医薬品市場：売上、2018年-2023年、2024年-2029年 ・世界の長鎖ペプチド医薬品市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の長鎖ペプチド医薬品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ホルモンペプチド製剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 長鎖ペプチド医薬品のグローバル主要企業は、Novartis、 Merck Serono、 Ferring Pharmaceuticals、 lpsen PHarma Biotech、 Lilly、 AstraZeneca、 SciClone Pharmaceuticals、 Sinopep Allsino Bio Pharmaceutical、 Takeda、 Roche、 Sanofi、 Ambio Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、長鎖ペプチド医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の長鎖ペプチド医薬品市場：タイプ別、2018年-2023年、2024年-2029年 世界の長鎖ペプチド医薬品市場：タイプ別市場シェア、2022年 ・ホルモンペプチド製剤、免疫調節ペプチド製剤、血管作動性ペプチド製剤、その他 世界の長鎖ペプチド医薬品市場：用途別、2018年-2023年、2024年-2029年 世界の長鎖ペプチド医薬品市場：用途別市場シェア、2022年 ・静脈注射、筋肉注射、皮下注射、その他 世界の長鎖ペプチド医薬品市場：地域・国別、2018年-2023年、2024年-2029年 世界の長鎖ペプチド医薬品市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における長鎖ペプチド医薬品のグローバル売上、2018年-2023年 ・主要企業における長鎖ペプチド医薬品のグローバル売上シェア、2022年 ・主要企業における長鎖ペプチド医薬品のグローバル販売量、2018年-2023年 ・主要企業における長鎖ペプチド医薬品のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Novartis、 Merck Serono、 Ferring Pharmaceuticals、 lpsen PHarma Biotech、 Lilly、 AstraZeneca、 SciClone Pharmaceuticals、 Sinopep Allsino Bio Pharmaceutical、 Takeda、 Roche、 Sanofi、 Ambio Pharmaceuticals ************************************************************* ・調査・分析レポートの概要 長鎖ペプチド医薬品市場の定義 市場セグメント 世界の長鎖ペプチド医薬品市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の長鎖ペプチド医薬品市場規模 世界の長鎖ペプチド医薬品市場規模：2022年 VS 2029年 世界の長鎖ペプチド医薬品市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの長鎖ペプチド医薬品の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の長鎖ペプチド医薬品製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ホルモンペプチド製剤、免疫調節ペプチド製剤、血管作動性ペプチド製剤、その他 長鎖ペプチド医薬品のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：静脈注射、筋肉注射、皮下注射、その他 長鎖ペプチド医薬品の用途別グローバル売上・予測 ・地域別市場分析 地域別長鎖ペプチド医薬品市場規模 2022年と2029年 地域別長鎖ペプチド医薬品売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Novartis、 Merck Serono、 Ferring Pharmaceuticals、 lpsen PHarma Biotech、 Lilly、 AstraZeneca、 SciClone Pharmaceuticals、 Sinopep Allsino Bio Pharmaceutical、 Takeda、 Roche、 Sanofi、 Ambio Pharmaceuticals ... |
This research report provides a comprehensive analysis of the Long Chain Modified Peptide Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Long Chain Modified Peptide Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Long Chain Modified Peptide Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Long Chain Modified Peptide Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Long Chain Modified Peptide Drugs market presents opportunities for various stakeholders, including Intravenous Injection, Intramuscular Injection. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Long Chain Modified Peptide Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Long Chain Modified Peptide Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Long Chain Modified Peptide Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Long Chain Modified Peptide Drugs market.
Market Overview: The report provides a comprehensive overview of the Long Chain Modified Peptide Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Hormone Peptide Drugs, Immunomodulatory Peptide Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Long Chain Modified Peptide Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Long Chain Modified Peptide Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Long Chain Modified Peptide Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Long Chain Modified Peptide Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Long Chain Modified Peptide Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Long Chain Modified Peptide Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Long Chain Modified Peptide Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Long Chain Modified Peptide Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Long Chain Modified Peptide Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Hormone Peptide Drugs
Immunomodulatory Peptide Drugs
Vasoactive Peptide Drugs
Others
Market segment by Application
Intravenous Injection
Intramuscular Injection
Hypodermic Injection
Others
Global Long Chain Modified Peptide Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Novartis
Merck Serono
Ferring Pharmaceuticals
lpsen PHarma Biotech
Lilly
AstraZeneca
SciClone Pharmaceuticals
Sinopep Allsino Bio Pharmaceutical
Takeda
Roche
Sanofi
Ambio Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Long Chain Modified Peptide Drugs, market overview.
Chapter 2: Global Long Chain Modified Peptide Drugs market size in revenue.
Chapter 3: Detailed analysis of Long Chain Modified Peptide Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long Chain Modified Peptide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Long Chain Modified Peptide Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long Chain Modified Peptide Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long Chain Modified Peptide Drugs Overall Market Size
2.1 Global Long Chain Modified Peptide Drugs Market Size: 2022 VS 2029
2.2 Global Long Chain Modified Peptide Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Long Chain Modified Peptide Drugs Players in Global Market
3.2 Top Global Long Chain Modified Peptide Drugs Companies Ranked by Revenue
3.3 Global Long Chain Modified Peptide Drugs Revenue by Companies
3.4 Top 3 and Top 5 Long Chain Modified Peptide Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Long Chain Modified Peptide Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Long Chain Modified Peptide Drugs Players in Global Market
3.6.1 List of Global Tier 1 Long Chain Modified Peptide Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Long Chain Modified Peptide Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Long Chain Modified Peptide Drugs Market Size Markets, 2022 & 2029
4.1.2 Hormone Peptide Drugs
4.1.3 Immunomodulatory Peptide Drugs
4.1.4 Vasoactive Peptide Drugs
4.1.5 Others
4.2 By Type – Global Long Chain Modified Peptide Drugs Revenue & Forecasts
4.2.1 By Type – Global Long Chain Modified Peptide Drugs Revenue, 2018-2023
4.2.2 By Type – Global Long Chain Modified Peptide Drugs Revenue, 2024-2029
4.2.3 By Type – Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Long Chain Modified Peptide Drugs Market Size, 2022 & 2029
5.1.2 Intravenous Injection
5.1.3 Intramuscular Injection
5.1.4 Hypodermic Injection
5.1.5 Others
5.2 By Application – Global Long Chain Modified Peptide Drugs Revenue & Forecasts
5.2.1 By Application – Global Long Chain Modified Peptide Drugs Revenue, 2018-2023
5.2.2 By Application – Global Long Chain Modified Peptide Drugs Revenue, 2024-2029
5.2.3 By Application – Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Long Chain Modified Peptide Drugs Market Size, 2022 & 2029
6.2 By Region – Global Long Chain Modified Peptide Drugs Revenue & Forecasts
6.2.1 By Region – Global Long Chain Modified Peptide Drugs Revenue, 2018-2023
6.2.2 By Region – Global Long Chain Modified Peptide Drugs Revenue, 2024-2029
6.2.3 By Region – Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Long Chain Modified Peptide Drugs Revenue, 2018-2029
6.3.2 US Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.3.3 Canada Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.3.4 Mexico Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Long Chain Modified Peptide Drugs Revenue, 2018-2029
6.4.2 Germany Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.3 France Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.4 U.K. Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.5 Italy Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.6 Russia Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.4.8 Benelux Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Long Chain Modified Peptide Drugs Revenue, 2018-2029
6.5.2 China Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.5.3 Japan Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.5.4 South Korea Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.5.6 India Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Long Chain Modified Peptide Drugs Revenue, 2018-2029
6.6.2 Brazil Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.6.3 Argentina Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Long Chain Modified Peptide Drugs Revenue, 2018-2029
6.7.2 Turkey Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.7.3 Israel Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Long Chain Modified Peptide Drugs Market Size, 2018-2029
6.7.5 UAE Long Chain Modified Peptide Drugs Market Size, 2018-2029
7 Long Chain Modified Peptide Drugs Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Long Chain Modified Peptide Drugs Major Product Offerings
7.1.4 Novartis Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Merck Serono
7.2.1 Merck Serono Company Summary
7.2.2 Merck Serono Business Overview
7.2.3 Merck Serono Long Chain Modified Peptide Drugs Major Product Offerings
7.2.4 Merck Serono Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.2.5 Merck Serono Key News & Latest Developments
7.3 Ferring Pharmaceuticals
7.3.1 Ferring Pharmaceuticals Company Summary
7.3.2 Ferring Pharmaceuticals Business Overview
7.3.3 Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Major Product Offerings
7.3.4 Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.3.5 Ferring Pharmaceuticals Key News & Latest Developments
7.4 lpsen PHarma Biotech
7.4.1 lpsen PHarma Biotech Company Summary
7.4.2 lpsen PHarma Biotech Business Overview
7.4.3 lpsen PHarma Biotech Long Chain Modified Peptide Drugs Major Product Offerings
7.4.4 lpsen PHarma Biotech Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.4.5 lpsen PHarma Biotech Key News & Latest Developments
7.5 Lilly
7.5.1 Lilly Company Summary
7.5.2 Lilly Business Overview
7.5.3 Lilly Long Chain Modified Peptide Drugs Major Product Offerings
7.5.4 Lilly Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.5.5 Lilly Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Long Chain Modified Peptide Drugs Major Product Offerings
7.6.4 AstraZeneca Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 SciClone Pharmaceuticals
7.7.1 SciClone Pharmaceuticals Company Summary
7.7.2 SciClone Pharmaceuticals Business Overview
7.7.3 SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Major Product Offerings
7.7.4 SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.7.5 SciClone Pharmaceuticals Key News & Latest Developments
7.8 Sinopep Allsino Bio Pharmaceutical
7.8.1 Sinopep Allsino Bio Pharmaceutical Company Summary
7.8.2 Sinopep Allsino Bio Pharmaceutical Business Overview
7.8.3 Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Major Product Offerings
7.8.4 Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.8.5 Sinopep Allsino Bio Pharmaceutical Key News & Latest Developments
7.9 Takeda
7.9.1 Takeda Company Summary
7.9.2 Takeda Business Overview
7.9.3 Takeda Long Chain Modified Peptide Drugs Major Product Offerings
7.9.4 Takeda Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.9.5 Takeda Key News & Latest Developments
7.10 Roche
7.10.1 Roche Company Summary
7.10.2 Roche Business Overview
7.10.3 Roche Long Chain Modified Peptide Drugs Major Product Offerings
7.10.4 Roche Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.10.5 Roche Key News & Latest Developments
7.11 Sanofi
7.11.1 Sanofi Company Summary
7.11.2 Sanofi Business Overview
7.11.3 Sanofi Long Chain Modified Peptide Drugs Major Product Offerings
7.11.4 Sanofi Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.11.5 Sanofi Key News & Latest Developments
7.12 Ambio Pharmaceuticals
7.12.1 Ambio Pharmaceuticals Company Summary
7.12.2 Ambio Pharmaceuticals Business Overview
7.12.3 Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Major Product Offerings
7.12.4 Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Revenue in Global Market (2018-2023)
7.12.5 Ambio Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Long Chain Modified Peptide Drugs Market Opportunities & Trends in Global Market
Table 2. Long Chain Modified Peptide Drugs Market Drivers in Global Market
Table 3. Long Chain Modified Peptide Drugs Market Restraints in Global Market
Table 4. Key Players of Long Chain Modified Peptide Drugs in Global Market
Table 5. Top Long Chain Modified Peptide Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Long Chain Modified Peptide Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Long Chain Modified Peptide Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Long Chain Modified Peptide Drugs Product Type
Table 9. List of Global Tier 1 Long Chain Modified Peptide Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Long Chain Modified Peptide Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Long Chain Modified Peptide Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Long Chain Modified Peptide Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Long Chain Modified Peptide Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Long Chain Modified Peptide Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Long Chain Modified Peptide Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Long Chain Modified Peptide Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Novartis Company Summary
Table 31. Novartis Long Chain Modified Peptide Drugs Product Offerings
Table 32. Novartis Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Novartis Key News & Latest Developments
Table 34. Merck Serono Company Summary
Table 35. Merck Serono Long Chain Modified Peptide Drugs Product Offerings
Table 36. Merck Serono Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Serono Key News & Latest Developments
Table 38. Ferring Pharmaceuticals Company Summary
Table 39. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Product Offerings
Table 40. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Ferring Pharmaceuticals Key News & Latest Developments
Table 42. lpsen PHarma Biotech Company Summary
Table 43. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Product Offerings
Table 44. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. lpsen PHarma Biotech Key News & Latest Developments
Table 46. Lilly Company Summary
Table 47. Lilly Long Chain Modified Peptide Drugs Product Offerings
Table 48. Lilly Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Lilly Key News & Latest Developments
Table 50. AstraZeneca Company Summary
Table 51. AstraZeneca Long Chain Modified Peptide Drugs Product Offerings
Table 52. AstraZeneca Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. AstraZeneca Key News & Latest Developments
Table 54. SciClone Pharmaceuticals Company Summary
Table 55. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Product Offerings
Table 56. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. SciClone Pharmaceuticals Key News & Latest Developments
Table 58. Sinopep Allsino Bio Pharmaceutical Company Summary
Table 59. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Product Offerings
Table 60. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Sinopep Allsino Bio Pharmaceutical Key News & Latest Developments
Table 62. Takeda Company Summary
Table 63. Takeda Long Chain Modified Peptide Drugs Product Offerings
Table 64. Takeda Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Takeda Key News & Latest Developments
Table 66. Roche Company Summary
Table 67. Roche Long Chain Modified Peptide Drugs Product Offerings
Table 68. Roche Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Roche Key News & Latest Developments
Table 70. Sanofi Company Summary
Table 71. Sanofi Long Chain Modified Peptide Drugs Product Offerings
Table 72. Sanofi Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Sanofi Key News & Latest Developments
Table 74. Ambio Pharmaceuticals Company Summary
Table 75. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Product Offerings
Table 76. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Ambio Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Long Chain Modified Peptide Drugs Segment by Type in 2022
Figure 2. Long Chain Modified Peptide Drugs Segment by Application in 2022
Figure 3. Global Long Chain Modified Peptide Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Long Chain Modified Peptide Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Long Chain Modified Peptide Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Long Chain Modified Peptide Drugs Revenue in 2022
Figure 8. By Type - Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 16. US Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 28. China Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Long Chain Modified Peptide Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Long Chain Modified Peptide Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Novartis Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Serono Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Lilly Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AstraZeneca Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Takeda Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Roche Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Sanofi Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)